Top Medical News
an hour ago
A large number of patients face new thrombotic events and organ damage in spite of therapy, while evolution toward connective tissue disease (CTD) is infrequent, according to a recent study.
Elvira Manzano, Yesterday
Treatment with interleukin (IL)-6 inhibitor tocilizumab improves anaemia markers in patients with rheumatoid arthritis (RA) compared with other disease-modifying antirheumatic drugs (DMARDs), real-world data have shown.
Tristan Manalac, 2 days ago
In low- and middle-income countries (LMICs), lifetime self-reported arthritis is significantly associated with mental health comorbidities like depression subtypes and anxiety, a recent study has shown.
Tristan Manalac, 4 days ago
Patients with systemic lupus erythematosus (SLE) without cardiovascular conditions have impaired endothelial function, a new case-controlled study has shown. Factors that contribute to endothelial dysfunction include renal diseases and diastolic hypertension.
5 days ago
The use of biological disease-modifying antirheumatic drugs (bDMARD) is associated with a minimal disease activity (MDA) status and remission in patients with psoriatic arthritis (PsA) as compared to conventional synthetic (cs)DMARD, according to a recent study.
6 days ago
Achieving remission is important to ensure work performance and activity in patients with rheumatoid arthritis (RA), according to a recent study.
06 Aug 2017
Low lean mass, either alone or in combination with high percentage fat mass, increases the risk of fragility in Korean males, a new study shows. In Korean females, body composition does not appear to be associated with fracture risk.
Special Reports
03 Apr 2017
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
07 Mar 2017
At the 17th Malaysian Society of Rheumatology/Singapore Society of Rheumatology Workshop, Associate Professor Susanna Proudman, a senior consultant in rheumatology from Australia, shared with the audience on the diagnosis and management of pulmonary arterial hypertension (PAH), with a focus on systemic sclerosis (SSc)-related PAH.
18 Aug 2016
During the combined meeting of the 46th Malaysian Orthopaedic Association Annual General Meeting/Annual Scientific Meeting and the 10th ASEAN Arthroplasty Association Meeting, Dr Joseph Pergolizzi spoke on the importance of chronic pain control and appropriate strategies to achieve this. Highlights of his presentation are summarized below.
09 Oct 2015
Calcium and vitamin D play a major role in the prevention and treatment of osteoporosis. In this exclusive interview with MIMS Doctor, Dr Yeap Swan Sim talks about the importance of calcium and vitamin D in bone health, as well as the current status of these micronutrients in local postmenopausal women.
13 May 2015
Recently, MIMS Doctor sat down with Associate Professor Dr Sabarul Afian Mokhtar to get his perspectives on the use of monoclonal antibody for the treatment of postmenopausal osteoporosis (PO) and also important learning from the International Osteoporosis Foundation (IOF) Regionals 5th Asia-Pacific Osteoporosis Meeting. Highlights from the interview are presented here.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.

Conference Reports
11 Jul 2017
Slideshow: Highlights from the European League Against Rheumatism (EULAR) Annual Congress 2017
Jackey Suen, 07 Jul 2017

The experimental drug ABT-981 fails to show significant improvements in pain and joint symptoms compared with placebo in patients with hand osteoarthritis (OA), according to a phase IIa trial presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held in Madrid, Spain. 

Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Dr. Joseph Delano Fule Robles, 27 Jun 2017

AMG-557, an inducible T-cell costimulator (ICOS) ligand inhibitor, showed efficacy and safety in a randomized multicentre trial that included patients with lupus arthritis from eight centres in the US, France, Malaysia and Germany. 

Christina Lau, 26 Jun 2017

Feelings of injustice and low socioeconomic status can have a significant impact on disease severity in patients with fibromyalgia, according to data from a large survey presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.

Jackey Suen, 23 Jun 2017

The fully-human immunocytokine dekavil (also known as F8-IL10) has demonstrated signs of safety and efficacy in patients with active rheumatoid arthritis (RA) in a phase I study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017.

Dr. Joseph Delano Fule Robles, 23 Jun 2017

Vobarilizumab, a nanobody consisting of an anti-interleukin 6 (IL-6) receptor domain developed for the treatment of rheumatoid arthritis (RA), is shown to be safe and efficacious in RA patients with inadequate response to methotrexate in a study presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 held recently in Madrid, Spain.